Patrys’s technology brings together all the advantages of antibodies—including specificity and safety—with those of DDR therapies, such as PARP inhibitors, that target DDR deficiencies ...

Clovis, meanwhile, reported that its PARP drug Rubraca (rucaparib ... and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

PARP proteins are involved in DNA repair ... He added that combination therapies, such as with antibody-drug conjugates where no combinatorial toxicity has been reported in preclinical models ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.